Regeneron Pharmaceuticals (WBO:REGN) ROE % Adjusted to Book Value : 4.65% (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Regeneron Pharmaceuticals ROE % Adjusted to Book Value?

Regeneron Pharmaceuticals's ROE % for the quarter that ended in Sep. 2024 was 18.36%. Regeneron Pharmaceuticals's PB Ratio for the quarter that ended in Sep. 2024 was 3.95. Regeneron Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was 4.65%.

Regeneron Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Regeneron Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals ROE % Adjusted to Book Value Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

5.85

6.49

14.85

6.25

4.36

Regeneron Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															4.56	4.90	2.76	5.08	4.65

Competitive Comparison of Regeneron Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Regeneron Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regeneron Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Regeneron Pharmaceuticals ROE % Adjusted to Book Value Calculation

Regeneron Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	16.04%	/	3.68
	=	4.36%

Regeneron Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	18.36%	/	3.95
	=	4.65%

Regeneron Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (WBO:REGN) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 1REGN:Italy 0R2M:UK RGO:Germany RGO:Germany REGN34:Brazil

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).